Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 5929 - 5936 of 12089 results
Massachusetts Legislature Proposes Limited Relief for Employer Medical Assistance Contribution (EMAC) Supplemental Payments
July 25, 2018| Blog| Viewpoint
Kavanaugh's Views On Arbitration Could Soon Be Tested
July 25, 2018| News
Ninth Circuit: No Ulterior Motive, No Bad Faith When Buying Claims to Block Confirmation
July 24, 2018| Blog| Viewpoint
Association Health Plan Perspectives (Part 1): Determining the Status of an AHP as “Fully-Insured”
July 24, 2018| Blog| Viewpoint
When Public Use Qualifies for the Experimental Use Exception to 35 U.S.C. § 102(b)
July 24, 2018| Blog| Viewpoint
Significant Drug Pricing Developments in July – Here’s What You Need To Know
July 24, 2018| Blog| Viewpoint
Biosimilars Action Plan Update: Public Hearing Scheduled
July 24, 2018| Blog| Viewpoint
Comcast Bows Out of Fox Bidding
July 24, 2018| News
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|